Takeda Pharmaceuticals North America, Inc., today announced the incorporation of Takeda Pharmaceuticals Mexico, S.A. de C.V. This expansion strengthens the company's North American presence, bolstering existing operations in the United States and Canada. Takeda Pharmaceuticals Mexico will be headquartered in Mexico City.
The Mexican pharmaceutical market is currently the 12th largest in the world and represents more than 25 percent of the Latin American market. Additionally, the prevalence of diabetes in Mexico is among the highest in the world.
"With a population of 109 million people, Mexico represents an important expansion opportunity for Takeda," said Shinji Honda, President and Chief Executive Officer, Takeda Pharmaceuticals North America, Inc. "The needs of patients in Mexico fit well with our product portfolio, so we are excited to bring important medicines to this vital region."
Takeda Mexico plans to file a new drug application with the Federal Commission for the Protection against Sanitary Risk (COFEPRIS) in 2010. Takeda focuses on a variety of therapeutic areas, including lifestyle-related diseases, oncology and urological diseases, central nervous system diseases, and gastroenterological diseases.
"For us, it is a pleasure that Takeda has chosen Mexico to start operations," said Bruno Ferrari, Chief Executive Officer of ProMexico, Mexico's Federal Government entity responsible for bringing direct foreign investment into Mexico as well as to support the country's foreign trade. "Takeda's experience is of great importance not only because of the company's contributions to Mexico's health system, but also the jobs that will be brought to Mexico's qualified labor force."
Combination therapy shows promising results in treating stage 3 melanoma